We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Biosensor Rapidly Detects Tumor Necrosis Factor Alpha

Doctor and patients in a hospital.
Credit: Tung Nguyen, Pixabay

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Biosensor Rapidly Detects Tumor Necrosis Factor Alpha"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 

Researchers with the SFU Nanodevice Fabrication Group are developing a new biosensor that can be used to screen for Alzheimer’s disease and other diseases. 


Their sensor works by detecting a particular type of small protein, in this case a cytokine known as Tumour Necrosis Factor alpha (TNF alpha), which is involved with inflammation in the body. Abnormal cytokine levels have been linked to a wide variety of diseases including Alzheimer’s disease, cancers, heart disease, autoimmune and cardiovascular disease.


TNF alpha can act as a biomarker, a measurable characteristic indicating health status. 


COVID-19 can also cause inflammatory reactions known as "cytokine storms", and studies have shown that cytokine inhibitors are an effective treatment for improving chances of survival.

Want more breaking news?

Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day.

Subscribe for FREE

“Our goal is to develop a sensor that’s less invasive, less expensive and simpler to use than existing methods,” says Engineering Science Assistant Professor Michael Adachi, the project’s co-lead.


“These sensors are also small and have potential to be placed in doctor’s offices to help diagnose different diseases, including Alzheimer’s disease.”


Adachi says that there are a number of established methods for detecting biomarker proteins such as enzyme-linked immunosorbent assay (ELISA) and mass spectrometry, but they have several drawbacks. These existing methods are expensive, samples need to be sent away to a lab for testing and it can take a day or more to receive the results.


He notes that their biosensor is extremely sensitive and can detect TNF alpha in very low concentrations (10 fM) – well below the concentrations normally found in healthy blood samples (200–300 fM).




Current screening tests for Alzheimer’s disease include a questionnaire to determine if the person has symptoms, brain imaging, or a spinal tap process which involves testing for the biomarker proteins in the cerebral spinal fluid of the potential patient.


The team has completed the proof-of-concept stage, proving that the two-electrode diode sensor is effective in detecting TNF alpha in a laboratory setting. They plan to test the biosensor in clinical trials to ensure it would be able to effectively detect biomarker proteins within a blood sample containing many different interfering proteins and other substances.


“We will continue testing the device’s ability to detect the same proteins using body fluid like blood samples,” says engineering science PhD student Hamidreza Ghanbari. “The other objective is to use the same device but a different receptor to detect proteins that are more specific to Alzheimer’s disease.”


The researchers have also filed a provisional patent application with the Technology Licensing Office (TLO) at SFU. The project takes an interdisciplinary approach combining leadership from Adachi in Engineering Science and professors Karen Kavanagh in the Dept. of Physics and Miriam Rosin in Biomedical Physiology and Kinesiology (BPK).


“We need to be sure each sensor is made exactly the same to the tolerance required for the concentration we’re trying to predict or detect, and that’s the real challenge,” says Kavanagh.


How it works


Kavanagh says their sensor depends on properties of a type of semiconductor that is being studied for its two-dimensional (2D) properties, molybdenum disulfide (MoS2). This compound has different properties compared to common semiconductors, silicon or gallium arsenide (GaAs), which are much more widely used and well-understood.


Thushani De Silva is an Engineering Science Master’s graduate who worked on the project and emphasizes that the device is based on electrical measurement.


“Basically, we have a semiconductor on the sensing area and when the targeted protein interacts with the sensor, it changes the electrical signal output,” she explains. “By measuring this change, we can measure the concentration of the protein present in the body fluids.”


The team uses a type of nanomaterial called two-dimensional materials, which are potentially atomically thin and used as the sensing layer. DNA sequences called aptamers are applied on top of these 2D materials.


Once a biomarker protein is introduced onto the sensor’s surface it causes minute changes in the electrical properties. By looking at the electrical output of the sensing layer they can determine the concentration of these biomarker proteins in a simple solution.


Reference: De Silva T, Fawzy M, Hasani A, et al. Ultrasensitive rapid cytokine sensors based on asymmetric geometry two-dimensional MoS2 diodes. Nat Commun. 2022;13(1):7593. doi: 10.1038/s41467-022-35278-2


This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.


Advertisement